the use of allogeneic transplantation in the era of checkpoint blockade therapy in hodgkin lymphoma
Published 2 years ago • 64 plays • Length 5:46Download video MP4
Download video MP3
Similar videos
-
2:33
transplantation in hodgkin lymphoma in the context of targeted immunotherapy
-
1:58
outcomes of patients with hodgkin lymphoma undergoing allohsct after pembrolizumab therapy
-
0:56
allogeneic transplantation in ctcl
-
1:09
the changing role of allosct in dlbcl in the era of novel agents
-
1:00
the role of non-covalent btk inhibitors in the treatment of non-hodgkin lymphoma
-
1:27
the promise of novel checkpoint inhibitors for the treatment of hl
-
1:13
efficacy of transplantation in hl
-
1:37
the role of ctdna in hodgkin lymphoma
-
6:24
tnb-486: interim results of a cd19/cd3 t-cell engager in r/r follicular lymphoma
-
12:49
3mensio ct pre-case planning: valve-in-valve tavr in homograft
-
21:06
lymphoid series part 1
-
1:59
hodgkin lymphoma: prognostic markers in the era of novel treatments
-
3:46
the impact of cytogenetic risk on outcomes of haploidentical transplantation in r/r aml
-
1:12
the evolving role of allosct in treatment of lymphoma
-
6:16
overview of novel restore and target treatment approach to classical hodgkin lymphoma
-
1:36
the changing role of chemotherapy in lymphoma and the value of novel immunotherapies
-
2:55
post-transplant pd1 blockade plus autologous lymphocytes in r/r hl
-
1:06
molecules versus cells for hodgkin lymphoma management
-
3:51
novel developments in relapsed/refractory hl: checkpoint inhibitors, bispecifics and car-t cells
-
0:59
developing lsc-targeting agents in aml: progress and current therapeutic capacity
-
1:25
how the role of transplant in all is evolving with the introduction of novel immunotherapies